Di Nuzzo Private Wealth, Inc. Halozyme Therapeutics, Inc. Transaction History
Di Nuzzo Private Wealth, Inc.
- $697 Million
- Q3 2025
A detailed history of Di Nuzzo Private Wealth, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Di Nuzzo Private Wealth, Inc. holds 16 shares of HALO stock, worth $1,088. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16
Previous 14
14.29%
Holding current value
$1,088
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding HALO
# of Institutions
635Shares Held
128MCall Options Held
408KPut Options Held
384K-
Black Rock Inc. New York, NY17.6MShares$1.2 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$833 Million0.01% of portfolio
-
State Street Corp Boston, MA5.94MShares$404 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$236 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$231 Million3.92% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.48B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...